文献速递神经免疫

基于个体 trough 浓度的那他珠单抗个性化延长间隔给药在多发性硬化中的前瞻性多中心试验

Personalized extended interval dosing of natalizumab in MS: A prospective multicenter trial.
PubMed 文献 · Neurology · 2020-07-20

结论认为稳定患者中个性化延长间隔给药可维持疗效且不诱导疾病活动复发。

要点

  • 基于个体 trough 浓度将那他珠单抗间隔从 4 周延长至 5–7 周未出现疾病活动复发。
  • 随访及延伸期无钆增强病灶、无新发/增大 T2 病灶、无复发。
  • EDSS 中位数基线及随访后均为 3.0(IQR 2.0–5.0),残疾进展稳定。

核心结论

  • 在无疾病活动的复发缓解型多发性硬化稳定患者中,基于个体那他珠单抗 trough 浓度的个性化延长间隔给药未诱导疾病活动复发,疗效得以维持。

研究设计与样本

  • 前瞻性多中心单臂试验,随访 1 年并设 1 年延伸期。
  • 给药间隔依据纵向那他珠单抗 trough 浓度制定,随访期间行 3 次月度 MRI、复发评估及残疾评分。

主要发现

  • 随访期间无患者出现钆增强病灶(95%CI 0%–7.4%)。
  • 随访及延伸期无新发/增大 T2 病灶(95%CI 0%–7.4%)及无复发(95%CI 0%–7.4%)。
  • EDSS 中位数基线为 3.0(IQR 2.0–5.0),随访后为 3.0(IQR 2.0–5.0)。

关键数值与推荐

  • 主要终点为 MRI 上钆增强病灶的发生,随访期间为 0(95%CI 0%–7.4%)。
  • 次要终点包括 MRI 新发/增大 T2 病灶、复发及 EDSS 进展,随访及延伸期均为 0 复发、0 新发/增大 T2 病灶(95%CI 0%–7.4%)。
  • 证据等级为 Class IV,提示个性化延长间隔给药在稳定复发缓解型多发性硬化患者中不导致疾病活动复发。

临床怎么用

  • 对入组前一年无疾病活动的复发缓解型多发性硬化稳定患者,可考虑依据个体那他珠单抗 trough 浓度将给药间隔从 4 周延长至 5–7 周。
  • 延长间隔期间需按方案进行 MRI、复发评估及 EDSS 残疾评分监测。

局限性

  • 单臂设计,无平行对照,证据等级为 Class IV。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine whether natalizumab efficacy is maintained when switching to personalized extended interval dosing based on individual natalizumab trough concentrations in patients with relapsing-remitting multiple sclerosis (RRMS). METHODS: This was a prospective multicenter single-arm trial with 1 year follow-up and a 1-year extension phase. Participants were adult persons with RRMS treated with natalizumab without disease activity in the year prior to enrollment. The natalizumab treatment interval was based on longitudinal natalizumab trough concentrations. Patients received 3 monthly MRI scans, relapse assessments, and disability scoring during follow-up. The primary endpoint was the occurrence of gadolinium-enhancing lesions on MRI. Secondary endpoints were new/enlarging T2 lesions on MRI and relapses and progression on the Expanded Disability Status Scale (EDSS) during follow-up and extension phase. RESULTS: Sixty-one patients were included. Eighty-four percent extended the interval from a 4-week interval to a 5- to 7-week interval. No patient developed gadolinium-enhancing lesions (95% confidence interval [CI] 0%-7.4%) during follow-up. No new/enlarging T2 lesions (95% CI 0%-7.4%) or relapses (95% CI 0%-7.4%) were reported during follow-up and in the extension phase. Median EDSS was comparable at baseline (3.0, interquartile range [IQR] 2.0-5.0) and after follow-up (3.0, IQR 2.0-5.0). CONCLUSION: Personalized extended interval dosing did not induce recurrence of MS disease activity. Natalizumab efficacy was maintained in stable patients with RRMS receiving personalized extended interval dosing based on individual natalizumab concentrations. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that personalized extended interval dosing of natalizumab does not result in recurrence of disease activity in stable patients with RRMS.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. van Kempen ZLE, Hoogervorst ELJ, Wattjes MP, et al. Personalized extended interval dosing of natalizumab in MS: A prospective multicenter trial. Neurology. 2020. PMID: 32690785. doi:10.1212/WNL.0000000000009995

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。